학술논문
Therapeutic opportunities of the IL-22-IL-22R1 system.
Document Type
Journal Article
Author
Source
Subject
*INTERLEUKIN-22
*T cells
*LYMPHOID tissue
*TUMOR necrosis factors
*PSORIASIS treatment
*COLITIS treatment
*ULCERATIVE colitis
*GRAFT versus host disease
*THERAPEUTICS
*
*
*
*
*
*
*
*
Language
ISSN
1474-1776
Abstract
Interleukin-22 (IL-22) is a key effector molecule that is produced by activated T cells, including T helper 22 (TH22) cells, TH17 cells and TH1 cells, as well as subsets of innate lymphoid cells. Although IL-22 can act synergistically with IL-17 or tumour necrosis factor, some important functions of IL-22 are unique to this cytokine. Data obtained over the past few years indicate that the IL-22-IL-22 receptor subunit 1 (IL-22R1) system has a high potential clinical relevance in psoriasis, ulcerative colitis, graft-versus-host disease, certain infections and tumours, as well as in liver and pancreas damage. This Review highlights current knowledge of the biology of the IL-22-IL-22R1 system, its role in inflammation, tissue protection, regeneration and antimicrobial defence, as well as the positive and potentially negative consequences of its therapeutic modulation. [ABSTRACT FROM AUTHOR]